ReproCELL Incorporated

4978

JP3974770004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 03:30:00 26/06/2024 BST			5-day change	1st Jan Change
138 ^JPY	+0.73%		+5.34%	-21.14%

2023	ReproCELL Incorporated announced that it has received ¥5.3 million in funding from Morgan Stanley MUFG Securities Co., Ltd.	CI
2023	ReproCELL Incorporated announced that it expects to receive ¥5.3 million in funding	CI

ReproCELL, Inc. announced that it has received ¥15.86 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm

December 18, 2016

On December 19, 2016, ReproCELL, Inc. (JASDAQ:4978) closed the transaction.

Latest news about ReproCELL Incorporated

ReproCELL Incorporated announced that it has received ¥5.3 million in funding from Morgan Stanley MUFG Securities Co., Ltd.	12-20	CI
ReproCELL Incorporated announced that it expects to receive ¥5.3 million in funding	12-04	CI
ReproCELL Incorporated Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23	CI
Histocell, S.L. announced that it expects to receive ?0.4 million in funding from ReproCELL Incorporated	07/11/22	CI
REPROCELL Signs Agreement to Prospectively Collect Samples for IFF's Microbiome Study	20/04/22	CI
Hoth Therapeutics Extends Partnership Agreement with REPROCELL	19/10/21	CI
Steminent Biotherapeutics, Inc announced that it expects to receive $0.8 million in funding from ReproCELL Incorporated	11/10/21	CI
Reprocell Signs Strategic Collaboration Agreement with TEXCELL to Boost Its GMP iPSC	01/09/21	CI
Curato Japan Co., Ltd. agreed to acquire unknown stake in Repro Curato Co., Ltd. from ReproCELL Incorporated.	15/07/21	CI
ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm	16/06/21	CI
ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm	31/05/21	CI
Lantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs	29/10/19	CI
Neucyte, Inc and Reprocell Enters into Distribution Partnership	25/09/19	CI
ReproCELL Incorporated acquired the remaining 0.87% stake in BioServe Biotechnologies Pvt Ltd. for INR 0.85 million.	09/07/19	CI
ReproCELL, Inc. announced that it has received ¥6.79 million in funding from Evolution Capital Management, LLC	10/06/18	CI
ReproCELL, Inc. announced that it expects to receive ¥6.79 million in funding from Evolution Capital Management, LLC	24/05/18	CI
ReproCELL, Inc. completed the acquisition of 98.28% stake in BioServe Biotechnologies Pvt Ltd from Cancer Genetics, Inc..	26/04/18	CI
ReproCELL, Inc. concluded a contract to acquire 98.28% stake in BioServe Biotechnologies Pvt Ltd from Cancer Genetics, Inc. for $1.9 million.	25/04/18	CI
Q Therapeutics, Inc. Announces Joint Venture With ReproCELL, Inc	23/04/18	CI
Q Therapeutics, Inc. Announces Research Collaboration with REPROCELL Inc	13/12/17	CI
BioServe Biotechnologies, Ltd. cancelled the acquisition of Stemgent Inc. and Biopta Inc. from Biopta Ltd and ReproCELL, Inc..	31/07/17	CI
ReproCELL, Inc. announced that it has received ¥15.86 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	18/12/16	CI
Kringle Pharma, Inc. announced that it has received ¥610 million in funding from a group of investors	04/12/16	CI
ReproCELL, Inc. announced that it expects to receive ¥15.86 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	01/12/16	CI
BioServe Biotechnologies, Ltd. agreed to acquire Stemgent Inc. and Biopta Inc. from Biopta Ltd and ReproCELL, Inc..	31/07/16	CI

ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ReproCELL Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
REPROCELL INCORPORATED	-21.14%	74.61M
CSL LIMITED	+2.98%	93.98B
SAMSUNG BIOLOGICS CO.,LTD.	-3.42%	37.69B
BIOGEN INC.	-13.75%	32.99B
UCB	+73.19%	28.27B
BIOMARIN PHARMACEUTICAL INC.	-11.88%	16.17B
INCYTE CORPORATION	+0.49%	14.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.95%	11.44B
ALTEOGEN INC.	+190.36%	10.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.07%	9.26B

Biopharmaceuticals

ReproCELL Incorporated

Equities

4978

JP3974770004

Pharmaceuticals

ReproCELL, Inc. announced that it has received ¥15.86 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm

Latest news about ReproCELL Incorporated

Chart ReproCELL Incorporated

Company Profile

Income Statement Evolution

Ratings for ReproCELL Incorporated

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals